The immunogenicity and safety of a Hib-MenAC vaccine: a non-inferiority randomized, observer-blind trial in infants aged 3-5 months

References

• Mccormick DW, Molyneux EM. Bacterial meningitis and Haemophilus influenzae type b conjugate vaccine, Malawi. Emerg Infect Dis. 2011;17(4):688–690.
   PubMed Web of Science ®Google Scholar
• Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813–819.
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11(1):17.
   PubMed Web of Science ®Google Scholar
• Gatchalian S, Palestroque E, De VI, et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis. 2008;12(3):278–288.
   PubMed Web of Science ®Google Scholar
• Hajjeh R. Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type b vaccine experience. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2827–2832.
   PubMed Web of Science ®Google Scholar
• Zarei AE, Almehdar HA, Redwan EM. Hib vaccines: past, present, and future perspectives. J Immunol Res. 2016;2016(5):1–18.
   Web of Science ®Google Scholar
• World Health Organization. Control of epidemic meningococcal disease. [Internet]. 2016. Available from: http://www.who.int/csr/resources/publications/meningitis/WHO_EMC_BAC_98_3_EN/en/
   Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2):S3–S11.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal meningitis Immunization [Internet]. 2016. Available from: http://www.who.int/immunization/diseases/meningitis/en/
   Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5(2):89–112.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. One of the recommended vaccines by disease. Meningococcal Vaccination [Internet]. 2016. Available from: https://www.cdc.gov/vaccines/vpd/mening/index.html
   Google Scholar
• Centers for Disease Control and Prevention. Haemophilus influenzae type B (Hib). New and Underused Vaccines [Internet]. 2016. Available from: https://www.cdc.gov/globalhealth/immunization/sis/vacs_detail.htm#Hib
   Google Scholar
• Ba O, Fleming JA, Dieye Y, et al. Hospital surveillance of childhood bacterial meningitis in Senegal and the introduction of Haemophilus influenzae type b conjugate vaccine. Am J Trop Med Hyg. 2010;83(6):1330–1335.
   PubMed Web of Science ®Google Scholar
• Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93(11):963–970.
   PubMed Web of Science ®Google Scholar
• Shetty S, Cohen AL, Edmond K, et al. A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. Pediatr Infect Dis J. 2010;29(7):653–661.
   PubMed Web of Science ®Google Scholar
• China Food and Drug Administration (CFDA). The standard guidlines for adverse reactions grading of vaccine clinical trials. [Internet]. 2016. Available from: http://www.sda.gov.cn/WS01/CL1616/83435.html
   Google Scholar
• Osborne K, Gay N, Hesketh L, et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol. 2000;29(2):362–368.
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol. 2003;10(5):780–786.
   PubMedGoogle Scholar
• Ambrosino DM, Landesman SH, Gorham CC, et al. Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children. J Infect Dis. 1986;153(1):1–7.
   PubMed Web of Science ®Google Scholar
• Mäkelä PH, Peltola H, Käyhty H, et al. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis. 1977;136(Suppl):S43–S50.
   PubMed Web of Science ®Google Scholar
• Käyhty H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147(6):1100.
   PubMed Web of Science ®Google Scholar
• Hu JL, Tao H, Li JX, et al. Safety and immunogenocity of a novel combined type b–serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old. Hum Vaccin Immunother. 2015;11(5):1120–1128.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381(9882):2024–2032.
   PubMed Web of Science ®Google Scholar
• Ward JI, Margolis HS, Lum MK, et al. Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet. 1981;1(8233):1281–1285.
   PubMed Web of Science ®Google Scholar
• Kurikka S, Käyhty H, Peltola H, et al. Neonatal immunization: response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics. 1995;95(6):815–822.
   PubMed Web of Science ®Google Scholar
• Thoon KC, Tee NW, Chew L, et al. Near disappearance of childhood invasive Haemophilus influenzae type b disease in Singapore. Vaccine. 2014;32(44):5862–5865.
   PubMed Web of Science ®Google Scholar
• Stefan N. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol. 2014;5:446.
   PubMed Web of Science ®Google Scholar
• Findlow J, Findlow H, Frankland S, et al. Evaluation of the safety and immunogenicity in United Kingdom laboratory workers of a combined Haemophilus influenzae type b and meningococcal capsular group C conjugate vaccine. J Occup Med Toxicol. 2014;9(26):1–7.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep. 2011;60(40):1391–1392.
   PubMedGoogle Scholar
• Riddell A, Buttery JP, McVernon J, et al. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide—CRM 197 with a meningococcal group C conjugate vaccine in healthy infants: challenge. Vaccine. 2007;25(19):3906–3912.
   PubMed Web of Science ®Google Scholar
• Habermehl P1, Leroux-Roels G, Sänger R, et al. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age. Hum Vaccin. 2010;6(8):640–651.
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63.
   PubMed Web of Science ®Google Scholar
• Avdicova M, Crasta PD, Hardt K, et al. Lasting immune memory against hepatitis B following challenge 10–11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11–12 months of age. Vaccine. 2015;33(23):2727–2733.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunization coverage [Internet]. 2016. Available from: http://www.who.int/mediacentre/factsheets/fs378/en/
   Google Scholar
• Lolekha S, Cooksley G, Chan V, et al. A review of Hib epidemiology in Asia. Southeast Asian J Trop Med Public Health. 2000;31(4):650–657.
   PubMedGoogle Scholar
• Chinese Center for Disease Control and Prevention. National Immunization Program. [Internet]. 2016. Available from: http://nip.chinacdc.cn/zstd/mycx/201209/t20120927_69741.htm
   Google Scholar
• World Health Organization. Meningococcal vaccines position paper [Internet]. 2015. Available from: http://www.who.int/immunization/policy/position_papers/meningococcal/en/
   Google Scholar